Event context and recent share performance

Liquidia (LQDA) has drawn investor attention after recent share price swings, with the stock up about 28% over the past 3 months but showing a loss of roughly 11% over the past month.

Looking beyond the recent pullback, Liquidia’s share price return has been choppy over the year. Its 1 year total shareholder return of about 149% and very large 5 year total shareholder return indicate strong long term upside participation for investors who stayed invested. This suggests recent momentum has cooled after a powerful multi year run as the market reassesses growth potential and risks around its pulmonary hypertension franchise.

If Liquidia’s swings have your attention, this could be a useful moment to compare it with other US$ healthcare names using healthcare stocks.

With Liquidia trading at US$30.99, sitting at a very large intrinsic discount and a sizeable gap to the average analyst price target, you have to ask yourself: is this a genuine mispricing, or is future growth already baked in?

Price to sales of 39x: Is it justified?

With Liquidia closing at US$30.99, the current 39x P/S suggests the market is assigning a rich revenue multiple compared with peers and the wider US pharmaceuticals group.

P/S compares the company’s market value to its revenue, which is often used for businesses that are still loss making, like Liquidia. It tells you how many dollars investors are paying today for each dollar of current sales.

In Liquidia’s case, that 39x P/S is far above the US pharmaceuticals industry average of 4.2x, and it also sits well above the peer group average of 10.3x. Compared with Simply Wall St’s estimated fair P/S of 14.6x, the current level looks stretched again and implies the share price is running well ahead of both sector norms and the ratio our model suggests the market could move toward if expectations were to cool.

Result: Price-to-sales of 39x (OVERVALUED)

However, you still need to weigh risks such as ongoing net losses of US$124.092 million, as well as potential clinical or regulatory setbacks related to its pulmonary hypertension pipeline.

Another way to look at value

Here is the twist. While the 39x P/S makes Liquidia look expensive next to the US pharmaceuticals average of 4.2x, our DCF model points the other way, with an estimated fair value of US$195.23 compared to the current US$30.99. Which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Liquidia for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 884 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Liquidia Narrative

If this take on Liquidia does not quite fit your view, you can stress test the same data yourself and shape your own story in a few minutes, starting with Do it your way.

A great starting point for your Liquidia research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Liquidia is on your radar, do not stop there, widen your watchlist with other clear, data driven ideas that could sharpen your overall portfolio.

• Spot emerging opportunities early by scanning these 3550 penny stocks with strong financials that pair higher risk with stronger underlying financials.
• Tap into long term growth themes by focusing on these 26 AI penny stocks positioned at the intersection of AI and potential market adoption.
• Strengthen your value hunting by reviewing these 884 undervalued stocks based on cash flows that trade at discounts based on cash flow estimates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.